{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:15:04Z","timestamp":1785428104159,"version":"3.56.0"},"reference-count":65,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research","award":["24590713"],"award-info":[{"award-number":["24590713"]}]},{"award":["24590713"],"award-info":[{"award-number":["24590713"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>L-asparaginase (ASNase) is a paradigmatic amino-acid depletion therapy that induces systemic asparagine starvation and remains foundational in acute lymphoblastic leukemia (ALL). Amino-acid metabolism constitutes a fundamental therapeutic vulnerability in hematologic malignancies, yet the determinants of response to systemic asparagine depletion remain incompletely defined. Asparagine synthetase (ASNS) regulates intracellular asparagine biosynthesis and functions as a stress-responsive metabolic node embedded within adaptive nutrient-sensing pathways. Emerging transcriptomic and proteomic evidence demonstrates that reduced ASNS expression is enriched in biologically distinct subsets of acute myeloid leukemia (AML), particularly those characterized by immature differentiation states and cytogenetic features associated with metabolic fragility, including inv(16) and chromosome 7-associated disease. Clinical experience in natural killer\/T-cell (NK\/T-cell) neoplasms provides proof-of-principle that enzymatic asparagine depletion can achieve durable therapeutic efficacy in tumors intrinsically dependent on extracellular amino-acid supply, establishing extranodal NK\/T-cell lymphoma (ENKTL) as a mechanistically aligned anchor indication beyond acute lymphoblastic leukemia. Integrative molecular analyses further indicate that ASNS deficiency functions as a permissive rather than deterministic biomarker, with therapeutic response modulated by lineage-specific metabolic wiring, adaptive stress signaling, and microenvironmental nutrient buffering. Advances in protein-anchored diagnostic platforms, including intracellular flow cytometry and quantitative proteomics, now enable operationalization of ASNS as a clinically actionable stratification marker. Mechanistic studies also suggest that amino-acid depletion may interact with apoptotic signaling networks, supporting rational combination strategies with targeted agents such as BCL-2 inhibitors. Collectively, these findings support a conceptual framework in which ASNS-low defines a context-dependent metabolic vulnerability rather than a uniform disease-wide predictor, underscoring the need for prospective biomarker-enriched clinical trials to establish ASNS-guided amino-acid depletion as a precision oncology strategy across heterogeneous myeloid and lymphoid malignancies.<\/jats:p>","DOI":"10.3390\/biom16060792","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:00:36Z","timestamp":1779955236000},"page":"792","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From ALL to Myeloid and NK Malignancies: Operationalizing \u201cASNS-Low\u201d for L-Asparaginase Repurposing and Combination Therapy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5519-8320","authenticated-orcid":false,"given":"Toshiyuki","family":"Kitoh","sequence":"first","affiliation":[{"name":"Laboratory of Pediatrics, School of Pharmacy, Aichi Gakuin University, Nagoya 464-8650, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/pbc.21213","article-title":"Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines","volume":"50","author":"Su","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2002-08-2446","article-title":"Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12; 21)+ pediatric ALL","volume":"101","author":"Stams","year":"2003","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2004-10-3892","article-title":"Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia","volume":"105","author":"Stams","year":"2005","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.exphem.2012.04.005","article-title":"Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase","volume":"40","author":"Hermanova","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2141.2003.04703.x","article-title":"In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia","volume":"123","author":"Okada","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109915","DOI":"10.18632\/oncotarget.18565","article-title":"Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-asparaginase","volume":"8","author":"Bertuccio","year":"2017","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-023-03591-1","article-title":"L-asparaginase as an efficient salvage therapy for refractory acute myeloid leukemia with chromosome 7 abnormalities: A case series","volume":"118","author":"Noguchi","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjh.15920","article-title":"Acute myeloid leukaemia niche regulates response to L-asparaginase","volume":"186","author":"Michelozzi","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI30235","article-title":"Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase","volume":"117","author":"Iwamoto","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/0008-5472.CAN-12-4402","article-title":"Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine","volume":"73","author":"Ehsanipour","year":"2013","journal-title":"Cancer Res."},{"key":"ref_11","first-page":"2070","article-title":"Antiproliferative effects of L-asparaginase in acute myeloid leukemia","volume":"20","author":"Chen","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2741\/4222","article-title":"L-asparaginase induces apoptosis in AML U937 cells via an AIF-mediated mechanism","volume":"19","author":"He","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"50829","DOI":"10.1074\/jbc.M409173200","article-title":"Amino acid deprivation induces the transcription rate of the human asparagine synthetase gene through a timed program of expression and promoter binding of nutrient-responsive basic region\/leucine zipper transcription factors as well as localized histone acetylation","volume":"279","author":"Chen","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/BJ20081706","article-title":"Transcriptional induction of the human asparagine synthetase gene during the unfolded protein response does not require the ATF6 and IRE1\/XBP1 arms of the pathway","volume":"417","author":"Gjymishka","year":"2009","journal-title":"Biochem. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/s41375-020-01080-6","article-title":"Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia","volume":"35","author":"Emadi","year":"2021","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1158\/1535-7163.MCT-18-1329","article-title":"Glutaminase activity of L-asparaginase contributes to durable preclinical activity against acute lymphoblastic leukemia","volume":"18","author":"Chan","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1038\/ncomms11457","article-title":"Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor","volume":"7","author":"Krall","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"bpad026","DOI":"10.1093\/biomethods\/bpad026","article-title":"A method for measurement of human asparagine synthetase activity and application to ASNS protein variants associated with ASNS deficiency","volume":"8","author":"Chang","year":"2023","journal-title":"Biol. Methods Protoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/224275a0","article-title":"Immunosuppression by L-asparaginase","volume":"224","author":"Schwartz","year":"1969","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1084\/jem.118.1.121","article-title":"Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo","volume":"118","author":"Broome","year":"1963","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12185-012-1111-0","article-title":"Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to AML therapy but responsive to L-asparaginase","volume":"96","author":"Takahashi","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_22","first-page":"374","article-title":"Clinical application of L-asparaginase to intractable acute non-lymphocytic leukemia","volume":"35","author":"Kitoh","year":"2000","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.leukres.2010.06.020","article-title":"A child with myeloid\/natural killer cell precursor acute leukemia treated successfully with AML-oriented chemotherapy incorporating L-asparaginase","volume":"34","author":"Morimoto","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000243725","article-title":"Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma","volume":"122","author":"Horikoshi","year":"2009","journal-title":"Acta Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF02982029","article-title":"Treatment of a child with myeloid\/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation","volume":"75","author":"Tezuka","year":"2002","journal-title":"Int. J. Hematol."},{"key":"ref_26","first-page":"35","article-title":"Establishment of flow cytometrical detection of asparagine synthetase protein in leukemia cells","volume":"15","author":"Hatta","year":"2005","journal-title":"Cytom. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hyb.2012.0014","article-title":"Evaluation of the asparagine synthetase level in leukemia cells by monoclonal antibodies","volume":"31","author":"Iwanari","year":"2012","journal-title":"Hybridoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood.V124.21.2233.2233","article-title":"Flow cytometric detection of asparagine synthetase protein in leukemia cells: Indication for L-asparaginase therapy","volume":"124","author":"Kitoh","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cyto.a.20623","article-title":"MIFlowCyt: The minimum information about a flow cytometry experiment","volume":"73","author":"Lee","year":"2008","journal-title":"Cytom. A"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1021\/acs.jproteome.4c00130","article-title":"Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia","volume":"23","author":"Narayanan","year":"2024","journal-title":"J. Proteome Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jprot.2007.11.009","article-title":"Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients","volume":"71","author":"Abbatiello","year":"2008","journal-title":"J. Proteom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.1073\/pnas.0832254100","article-title":"Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS","volume":"100","author":"Gerber","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1038\/s41467-020-18904-9","article-title":"Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies","volume":"11","author":"Xuan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4939-3524-6_13","article-title":"Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays","volume":"1410","author":"Whiteaker","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.2147\/OTT.S155930","article-title":"Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer\/T-cell lymphoma in vivo and in vitro","volume":"11","author":"Liu","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1158\/1078-0432.CCR-18-1844","article-title":"Epigenetic silencing affects L-asparaginase sensitivity and predicts outcome in T-ALL","volume":"25","author":"Touzart","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhou, R., Liang, T., Li, T., Huang, J., and Chen, C. (2023). Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1070069"},{"key":"ref_39","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2023). Evaluation of Qualitative, Binary Output Examination Performance, CLSI. [3rd ed.]. CLSI guideline EP12."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.5858\/arpa.2013-0610-CP","article-title":"Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.5858\/arpa.2023-0483-CP","article-title":"Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update","volume":"148","author":"Goldsmith","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_42","unstructured":"U.S. Food and Drug Administration (2014). In Vitro Companion Diagnostic Devices: Guidance for Industry and FDA Staff."},{"key":"ref_43","unstructured":"U.S. Food and Drug Administration (2023). Companion Diagnostics, In Vitro Diagnostics overview."},{"key":"ref_44","unstructured":"U.S. Food and Drug Administration (2026). List of Cleared or Approved Companion Diagnostic Devices, In Vitro and Imaging Tools."},{"key":"#cr-split#-ref_45.1","unstructured":"The European Parliament, and The Council of the European Union (2017). Regulation"},{"key":"#cr-split#-ref_45.2","unstructured":"(EU) 2017\/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices (IVDR). Off. J. Eur. Union, 5, 176-332."},{"key":"ref_46","unstructured":"European Medicines Agency (EMA) (2022). Guidance on the Procedural Aspects for the Consultation to the EMA by a Notified Body on Companion Diagnostics, EMA. EMA\/198592\/2022."},{"key":"ref_47","unstructured":"(2022). Medical Laboratories\u2014Requirements for Quality and Competence (Standard No. ISO 15189:2022)."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal NK\/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma: A phase II study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"35412","DOI":"10.18632\/oncotarget.8643","article-title":"Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK\/T-cell lymphoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2141.2005.05694.x","article-title":"Selective apoptosis of natural killer-cell tumours by L-asparaginase","volume":"130","author":"Ando","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/1042819031000067873","article-title":"Successful treatment with Erwinia L-asparaginase for recurrent natural killer\/T cell lymphoma","volume":"44","author":"Matsumoto","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","first-page":"1993","article-title":"Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK\/T-cell lymphoma","volume":"32","author":"Sakamoto","year":"2005","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11864-023-01104-0","article-title":"Targeting glutamine metabolism as an attractive therapeutic strategy for acute myeloid leukemia","volume":"24","author":"Xiao","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.2024024837","article-title":"A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia","volume":"145","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/bjh.19652","article-title":"L-asparaginase monotherapy as an encouraging approach towards acute fulminant chronic active Epstein-Barr virus infection","volume":"205","author":"Furukawa","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.2169\/internalmedicine.4672-24","article-title":"Successful Allogeneic Hematopoietic Stem Cell Transplantation for Nodal Epstein-Barr Virus-positive T\/NK-cell Lymphoma","volume":"64","author":"Ichikawa","year":"2025","journal-title":"Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e000858","DOI":"10.1136\/esmoopen-2020-000858","article-title":"Managing toxicities with asparaginase-based therapies in adult ALL: Summary of an ESMO Open-Cancer Horizons roundtable discussion","volume":"5","author":"Burke","year":"2020","journal-title":"ESMO Open"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jth.14671","article-title":"The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH","volume":"18","author":"Zwicker","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: Results from the NOPHO ALL2008 treatment of patients 1-45 years of age","volume":"38","author":"Rank","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_63","unstructured":"U.S. Food and Drug Administration (2019). Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products: Guidance for Industry."},{"key":"ref_64","unstructured":"U.S. Food and Drug Administration (2019). Adaptive Design Clinical Trials for Drugs and Biological Products: Guidance for Industry."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/792\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:43:21Z","timestamp":1780652601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["biom16060792"],"URL":"https:\/\/doi.org\/10.3390\/biom16060792","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}